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Sleep andWakefulness Are Controlled by Ventral Medial
Midbrain/Pons GABAergic Neurons in Mice
Yohko Takata, XYo Oishi, XXu-Zhao Zhou, Emi Hasegawa, Koji Takahashi, XYoan Cherasse, XTakeshi Sakurai,
and XMichael Lazarus
International Institute for Integrative Sleep Medicine (WPI-IIIS), University of Tsukuba, Tsukuba, Ibaraki 305-8575, Japan
Sleep–wakebehavior is controlledby awide range of neuronal populations in themammalianbrain.Although the ventralmidbrain/pons
(VMP) area is suggested to participate in sleep–wake regulation, the neuronal mechanisms have remained unclear. Here, we found that
nonspecific cell ablation or selective ablation of GABAergic neurons by expressing diphtheria toxin fragment A in the VMP inmalemice
induced a large increase in wakefulness that lasted at least 4 weeks. In contrast, selective ablation of dopaminergic neurons in the VMP
had little effect on wakefulness. Chemogenetic inhibition of VMP GABAergic neurons also markedly increased wakefulness. The wake-
promoting effect of the VMP GABAergic neuron ablation or inhibition was attenuated to varying degrees by the administration of
dopamine D1 or D2/3 receptor antagonists and abolished by the administration of both antagonists together. In contrast, chemogenetic
activation of VMP GABAergic neurons very strongly increased slow-wave sleep and reduced wakefulness. These findings suggest that
VMP GABAergic neurons regulate dopaminergic actions in the sleep–wake behavior of mice.
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Introduction
One potential function of sleep is to conserve energy by enforcing
inactivity when activity is not beneficial (Siegel, 2009). Con-
versely, when varying ecological demands favor wakefulness, an-
imals may have the ability to dispense with sleep. The circuit
mechanisms underlying the control of wakefulness to adapt an
animal’s amount of sleep to its behavior, however, are largely
unknown.
We recently identified indirect pathway neurons in the nu-
cleus accumbens as sleep-controlling neurons (Oishi et al.,
2017b). The nucleus accumbens is innervated by ventral tegmen-
tal area (VTA) neurons in the ventral portion of the midbrain
(Taylor et al., 2014; Oishi and Lazarus, 2017). Although we and
others have reported that activation of the VTA dopaminergic
neurons strongly induces wakefulness (Eban-Rothschild et al.,
2016; Taylor et al., 2016; Oishi et al., 2017a), the role of this
midbrain area in sleep–wake regulation remains unclear because
the findings are conflicting. In rats, neurotoxic lesions of the cells
in this area with hypocretin-2-saporin have no effect on sleep–
wake behavior (Gerashchenko et al., 2006). In cats, electrolytic
lesions of the ventral midbrain area, including the VTA, has no
significant effect on sleep–wake behavior (Jones et al., 1973),
whereasN-methyl-D-aspartate lesions of cells in an area contain-
ing the VTA produce insomnia (Lai et al., 1999).
In the present study, we used an ablation technique based on
the viral expression of diphtheria toxin fragment A (DTA) and
found that nonspecific or GABAergic neuron-specific ablations
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Significance Statement
Current understanding of the neuronal mechanisms and populations that regulate sleep–wake behavior is incomplete. Here, we
identified a GABAergic ventral midbrain/pons area that is necessary for controlling the daily amount of sleep and wakefulness in
mice. We also found that these inhibitory neurons control wakefulness by suppressing dopaminergic systems. Surprisingly,
activation of these neurons strongly induced slow-wave sleep while suppressing wakefulness. Our study reveals a new brain
mechanism critical for sleep–wake regulation.
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in the ventral medial midbrain/pons area (VMP) at the junction
of the ventral medial midbrain and pons largely increased wake-
fulness in mice. The increased wakefulness was also observed
after chemogenetic inhibition of the VMP GABAergic neurons.
Using pharmacologic tools, we further demonstrated that this
arousal effect was mediated by dopaminergic systems. These
findings indicate that theVMPGABAergic cells are critical for the
control of sleep–wake behavior.
Materials andMethods
Mice and chemicals.We used the following mouse lines: C57BL/6J wild-
type (WT, Charles River Laboratories), dopamine transporter (DAT)-
Cre (Ba¨ckman et al., 2006) (The Jackson Laboratory 006660), and
vesicular GABA transporter (VGAT)-Cre (Vong et al., 2011) (kindly
provided by Dr. Bradford Lowell, Harvard Medical School). Male mice
(8–20weeks, 25–35 g)were used for the behavioral studies and housed in
insulated sound-proof recording chambers maintained at an ambient
temperature of 23 0.5°C with 55 3% humidity on a 12 h light/dark
cycle (lights on at 8:00) and provided food and water ad libitum. All
experiments were performed in accordance with the Animal Care Com-
mittee of the University of Tsukuba and every effort was made to mini-
mize the number of animals used as well as any pain or discomfort.
Clozapine-N-oxide (CNO, Millipore-Sigma), the selective D1 recep-
tor antagonist SCH23390 (Millipore-Sigma), the selective D2/D3 recep-
tor antagonist raclopride (Millipore-Sigma), and histamine H1 receptor
antagonist ketotifen (Tokyo Chemical) were dissolved in saline.
Plasmids and adeno-associated viral vectors (AAVs). To generate the
pAAV-CMV-FLEX-DTA plasmid, a FLEX-DTA cassette (see Fig. 1A)
was synthesized by Eurofins Genomics K.K. and inserted between the
ClaI and BamHI restriction sites in a pAAV-MCS vector (Stratagene). To
generate the pAAV-CMV-FLEX-hrGFP plasmid, the DTA fragment be-
tween the AscI andNheI restriction sites in pAAV-CMV-FLEX-DTAwas
replaced with the hrGFP coding sequence. The plasmids pAAV-hSyn-
FLEX-hM4Di-mCherry and pAAV-hSyn-FLEX-hM3Dq-mCherry
(Krashes et al., 2011)were kindly provided byDr. BryanRoth (University
of North Carolina School of Medicine, Chapel Hill, NC). The plasmids
generated in this study will be deposited in Addgene.
pAAV-CMV-FLEX-DTA, pAAV-CMV-FLEX-hrGFP, pAAV-CMV-
Cre (Lazarus et al., 2011), pAAV-hSyn-FLEX-hM4Di-mCherry, or
pAAV-hSyn-FLEX-hM3Dq-mCherry were packaged in the AAV of se-
rotype rh10 using 293A cells as described previously (Kaur et al., 2017;
Oishi et al., 2017a,b).
Surgery. For brain microinjections, mice anesthetized with pentobar-
bital (60 mg kg1, i.p.) were injected bilaterally into the VMP (3.4 mm
posterior and 0.2 mm lateral to bregma, 4.4 mm below the dura) with 60
nl per injection of AAV using a glass micropipette and an air pressure
injector system. To generate mice with nonselective cell-type ablation,
WT mice were injected with a mixture (1:1) of AAV-FLEX-DTA (8.6
1010 particles ml1) and AAV-Cre (1.5 1011 particles ml1) or AAV-
FLEX-DTA alone. To generate mice with dopaminergic or GABAergic
neuron ablation, DAT-Cre mice or VGAT-Cre mice, respectively, were
injected with AAV-FLEX-DTA or AAV-FLEX-hrGFP (1.5 1011 parti-
clesml1). For the chemogenetic experiments, theVGAT-Cremicewere
injected with AAV-FLEX-hM4Di-mCherry (1.1 1011 particles ml1)
or AAV-FLEX-hM3Dq-mCherry (1.1 1011 particles ml1).
Mice were also chronically implanted with electroencephalography
(EEG) and electromyography (EMG) electrodes for polysomnography,
as described previously (Oishi et al., 2016). Briefly, the implant com-
prised two stainless steel screws serving as EEG electrodes and two insu-
lated, Teflon-coated silver wires were placed bilaterally into the trapezius
muscles to serve as EMGelectrodes. The electrodes were fixed to the skull
with dental acrylic.
EEG/EMG recordings. After allowing 1–2 weeks for postoperative re-
covery and transgene expression, the mice were connected with EEG/
EMG recording cables. The EEG/EMG signals were amplified and
filtered (EEG: 0.5–64 Hz, EMG: 16–64 Hz), digitized at a sampling rate
of 128 Hz, and recorded using SLEEPSIGN software (Kissei Comtec).
Vigilance states were scored offline by characterizing 10 s epochs into
three stages: (1) awake, (2) slow-wave sleep (SWS), and (3) rapid eye
movement sleep (REMS) according to standard criteria (Oishi et al.,
2016).
Pharmacologic and chemogenetic experiments.After baseline recordings
for 24 h, VGAT-CreDTA/VMP mice were administered saline, 0.03 mg
kg1 SCH23390, 2mg kg1 raclopride, or 10mg kg1 ketotifen at 10:00.
Eachmouse received all combinations of dopamine receptor antagonists
in a random order with at least 3 d intervals between drug administra-
tions. A separatemouse group received ketotifen.Doses of the drugswere
selected based on previous studies (Qu et al., 2008; Unno et al., 2012;
Oishi et al., 2017a). For chemogenetic inhibition, VGAT-CreM4/VMP
mice were injected intraperitoneally with saline or 3 mg kg1 CNO at
10:00 on 2 consecutive days. For chemogenetic activation, each VGAT-
CreM3/VMP mouse received intraperitoneally saline or different doses
(0.3, 0.9, and 2.7 mg kg1) of CNO at 20:00 with at least 3 d intervals
between drug administrations.
Histology. Under deep anesthesia with an overdose of chloral hydrate
(500 mg kg1, i.p.), animals were perfused intracardially with saline
followed by neutral buffered 10% formalin. Brains were then placed in
20% sucrose overnight at 4°C to reduce freezing artifact. The brains were
sectioned at 40 m on a freezing microtome.
For immunohistochemistry, sections were incubated in 0.3% hydro-
gen peroxide and then overnightwith rabbit anti-DsRed (1:10,000, Clon-
tech, catalog #632496, RRID:AB_10013483), mouse anti-NeuN (1:2000,
Millipore, catalog #MAB377, RRID:AB_2298772), or rabbit anti-
tyrosine hydroxylase (TH; 1:20,000, Millipore, catalog #AB152, RRID:
AB_390204). Sections were incubated for 2 h in biotinylated antibody
(1:1000, Jackson ImmunoResearch Laboratories) and treated with
avidin–biotin complex (1:1000; Vectastain ABC Elite kit, Vector Labo-
ratories) for 1 h. Immunoreactive cells were visualized by reaction with
3,3-diaminobenzidine and 0.01% hydrogen peroxide.
For in situ hybridization, we generated a 918-bp digoxigenin-labeled
riboprobe for VGAT mRNA by PCR amplification (primers: forward,
gcatgttcgtgctgggcctacc; reverse, cagcgcagcgtcagcccccag conjugated with
the T7 promoter) usingmouse tail genomic DNA as a template, followed
by in vitro transcription. Sections were then incubated with a 1 g ml1
concentration of theVGATprobe in 5 sodiumcitrate buffer containing
50% formamide at 50°C overnight, washed in 1 saline sodium citrate
buffer at 50°C, incubated with alkaline phosphatase conjugated anti-
digoxigenin antibody (1:500, Roche) overnight, and visualized by reac-
tion with 5-bromo-4-chloro-3-indolyl phosphate/nitro blue tetrazolium
(BCIP/NBT, Millipore-Sigma).
For double-labeling of c-Fos and mCherry, we immunostained c-Fos
with rabbit anti-c-Fos antibody (1:2000, Millipore, catalog #ABE457,
RRID:AB_2631318), peroxidase-conjugated anti-rabbit antibody (1:
250, Jackson ImmunoResearch Laboratories), and tyramide-conjugated
fluorescein (PerkinElmer). mCherry-positive cells were identified by the
native red fluorescence of mCherry. Images were analyzed with a confo-
cal laser scanning microscope LSM800 (Carl Zeiss).
For quantitative histologic analysis, we counted cells positive for TH,
VGATmRNA, c-Fos, ormCherry using a counting box placed bilaterally
in the VMP.We placed a 500 650mboxwith the ventral medial edge
at the center of the interpeduncular nucleus and themedial border along
the midline 3.8 mm posterior to bregma. The anterior–posterior coordi-
nates were obtained from the Paxinos and Franklin mouse brain atlas
(Paxinos and Franklin, 2001). The cell counts were adjusted using the
Abercrombie correction factor (Guillery, 2002).
Electrophysiology. Five-week-old VGAT-Cre mice were injected in
the VMP with AAV-FLEX-hM4Di-mCherry or AAV-FLEX-hM3Dq-
mCherry. After 1–2 weeks, the mice were decapitated under deep anes-
thesia with isoflurane (Pfizer). Brains were extracted and cooled in
ice-cold cutting solution containing the following (in mM): 125 choline
chloride, 25 NaHCO3, 10 D()-glucose, 7 MgCl2, 2.5 KCl, 1.25
NaH2PO4, and 0.5 CaCl2 bubbled with O2 (95%) and CO2 (5%). Hori-
zontal brain slices (250mthick) including theVMPwere preparedwith
a vibratome (VT1200S, Leica) and maintained for 1 h at room tempera-
ture in artificial CSF (ACSF) containing the following (inmM): 125NaCl,
26 NaHCO3, 10 D()-glucose, 2.5 KCl, 2 CaCl2, and 1 MgSO4 bubbled
with O2 (95%) and CO2 (5%). The electrodes (5–8M) were filled with
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Figure 1. Ablation of the VMP increaseswakefulness.A,WTmicewere injectedwith AAV-FLEX-DTA andAAV-Cre into the VMP.B, C, Brain sectionswere stained against NeuN to confirm that the
VMP neurons were ablated in the mice injected with AAV-FLEX-DTA and AAV-Cre (WT DTA/VMP mice; B). No deficiency in VMP neurons was detected in mice injected with only AAV-FLEX-DTA
(WT Ctrl/VMP mice; C). Dashed line delineates the area with neuronal loss in a WT DTA/VMP mouse. Scale bar, 500 m. D, Superimposed neuronal loss areas in the (Figure legend continues.)
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an internal solution containing the following (in mM): 125 K-gluconate,
10 HEPES, 10 phosphocreatine, 4 NaCl, 4 ATP, 2 MgCl2, 0.4 GTP, and
0.2 EGTA, pH 7.3, adjusted with KOH). Firing of hM4Di-mCherry or
hM3Dq-mCherry-expressing neurons was recorded in the current-
clamp mode at a temperature of 30°C, which was maintained by perfu-
sion of preheated ACSF before and after 5 M CNO application. The
combination of a MultiClamp 700B amplifier, a Digidata 1440A A/D
converter, and Clampex 10.3 software (Molecular Devices) was used to
control membrane voltage and data acquisition.
Experimental design and statistical analysis. For behavioral experi-
ments, the numbers of mice used were chosen based on expected varia-
tions between animals and variability of AAV microinjections.
Data are presented as the mean and SEM. Statistical analyses were
performed using GraphPad Prism software. Statistical comparisons be-
tween two groups were performed using the unpaired (see Figs. 1H–M;
2F, J–O; 3F, J,K,M–O, and 8C,D) or paired (see Figs. 4C,D; 5D,F–H, and
7C) two-tailed Student’s t test. For t tests, the normality of each dataset
was established using the Kolmogorov–Smirnov test. Comparisons
amongmultiple parameters were performed by a mixed-model ANOVA
followed by Sidak’s post hoc comparisons (see Figs. 1E–G,N–P; 2G–
I,P–R, and 3G– I,P–S), one-way repeated-measures ANOVA followed by
Tukey’s post hoc comparisons (see Figs. 4A,B and 7G–O), or two-way
repeated-measures ANOVA followed by Sidak’s post hoc comparisons
(Figs. 5E, I; 6A–E, and 7D–F,P,Q). In all cases, p 0.05 was considered
significant.
Results
VMP cell deficiency increases wakefulness in mice
To examine the role of ventral midbrain neurons in sleep–wake
regulation, we first nonselectively ablated cells in this brain area
in WT mice by stereotaxic co-microinjection of AAV carrying
Cre-dependent DTA (AAV-FLEX-DTA) and Cre recombinase
(AAV-Cre; WTDTA/VMP mice; Fig. 1A,B). Because the ablation
was observed not only in the ventral medial portion of the mid-
brain, but also in a part of the pons as confirmed by immuno-
staining for the neuronal marker NeuN (Fig. 1B–D), the ablated
area is hereafter referred to as the VMP. In all cases, the ablated
area largely included the VTA and almost none of the substantia
nigra. Control mice were only injected with AAV-FLEX-DTA
into the VMP and did not express DTA in the VMP due to the
absence of Cre recombinase (WTCtrl/VMP mice; Fig. 1C). At 1
week after the AAV injections, EEG and EMG recordings of the
mice were analyzed to assess the baseline sleep–wake behavior of
the animals. Compared withWTCtrl/VMPmice,WTDTA/VMPmice
exhibited largely increased wakefulness, especially in the first half
of the light period, when mice typically show high levels of sleep,
but also in the second half of the dark period (F(1,10)	 66.7, p
0.0001, ANOVA; Fig. 1E). Concomitantly,WTDTA/VMPmice had
a lower amount of SWS (F(1,10)	 60.9, p 0.0001, ANOVA; Fig.
1F) and REMS (F(1,10)	 73.4, p 0.0001, ANOVA; Fig. 1G).We
then examined the pattern of waking inWTDTA/VMP andWTCtrl/VMP
mice. The mean duration of wake episodes in the WTDTA/VMP
mice was 3.1 (t(10)	 3.05, p	 0.012, unpaired t test; light period)
and 7.7 (t(10) 	 4.03, p 	 0.0024, unpaired t test; dark period)
times longer than that of wake episodes in the WTCtrl/VMP mice
(Fig. 1H), whereas the number of wake episodes was lower by
37% (t(10)	 2.85, p	 0.0172, unpaired t test) and 85% (t(10)	
5.44, p 	 0.0003, unpaired t test) in the light and dark periods,
respectively (Fig. 1K), suggesting that ablation of VMP cells effi-
ciently consolidates wakefulness. Themean duration of SWS and
REMS was unchanged (light period SWS: t(10)	 0.57, p	 0.58;
dark period SWS: t(10) 	 1.46, p 	 0.17; light period REMS:
t(10) 	 0.38, p 	 0.71; dark period REMS: t(9) 	 0.14, p 	 0.89,
unpaired t test; Fig. 1 I, J), whereas the episode number was de-
creased in WTDTA/VMP mice (light period SWS: t(10)	 3.42, p	
0.0066; dark period SWS: t(10) 	 5.71, p 	 0.0002; light period
REMS: t(10)	 4.42, p	 0.0013; dark period REMS: t(10)	 6.89,
p 0.0001, unpaired t test; Fig. 1L,M). Animals have the ability
to adapt their sleep–wake behavior after the loss of brain cells
over the course of several weeks (Lai et al., 1999; Gerashchenko et
al., 2006), so we measured EEG activity for up to 4 weeks after
surgery. Although the wake amount of WTDTA/VMP mice in the
dark period reached the same level as that of theWTCtrl/VMPmice
between 2 and 4 weeks after surgery, theWTDTA/VMPmice main-
tained significantly higher amounts of wakefulness in the light
period, even at 4 weeks after surgery (light period: F(1,10)	 21.4,
p	 0.0009; dark period: F(1,10)	 15.5, p	 0.0028, ANOVA; Fig.
1N). SWS and REMS amount were concomitantly lower in
WTDTA/VMP mice especially during the light period (light period
SWS: F(1,10)	 18.1, p	 0.0017; dark period SWS: F(1,10)	 16.2,
p 	 0.0024; light period REMS: F(1,10) 	 26.0, p 	 0.0005; dark
period REMS: F(1,10) 	 6.50, p 	 0.0289, ANOVA; Fig. 1O,P).
These findings suggest that VMP cells contribute to the sleep–
wake behavior of mice and that the absence of these cells cannot
be compensated for by other brain areas, at least in the light
period.
VMP dopaminergic neuron deficiency has little to no effect
on wakefulness
The VMP includes the VTA, which contains dopaminergic
(
60%) and GABAergic (
35%) neurons (Oishi and Lazarus,
2017). Because VTA dopaminergic neurons are implicated in the
regulation of wakefulness (Eban-Rothschild et al., 2016; Oishi et
al., 2017a), we next selectively ablated these neurons in the VMP
to determine whether they contribute to baseline wakefulness in
mice. To generate mice with VMP dopaminergic neuron defi-
ciency (DAT-CreDTA/VMP mice; Fig. 2A–C), AAV-FLEX-DTA
wasmicroinjected into the VMP ofDAT-Cremice expressing the
Cre protein exclusively in dopaminergic neurons (Ba¨ckman et al.,
2006). Mice expressing humanized Renilla reniformis-derived
green fluorescent protein (hrGFP) in VMP dopaminergic neu-
rons were generated as a control (DAT-CrehrGFP/VMP mice; Fig.
2D,E). The number of cells positive for TH, a marker of dopa-
minergic neurons, was decreased by 94% in the VMP of DAT-
CreDTA/VMP mice compared with DAT-CrehrGFP/VMP mice
(t(10)	 9.30, p 0.0001, unpaired t test; Fig. 2F). Comparedwith
the DAT-CrehrGFP/VMP mice, DAT-CreDTA/VMP mice exhibited
no significant differences in the time course of wakefulness
(F(1,10) 	 0.0135, p 	 0.91, ANOVA; Fig. 2G), SWS (F(1,10) 	
0.0013, p 	 0.97, ANOVA; Fig. 2H), or REMS (F(1,10) 	 0.137,
p	 0.72, ANOVA; Fig. 2I) or in the mean duration (light period
wakefulness: t(10) 	 1.02, p 	 0.33; dark period wakefulness:
t(10)	 0.957, p	 0.36; light period SWS: t(10)	 0.851, p	 0.41;
dark period SWS: t(10) 	 0.307, p 	 0.77; light period REMS:
t(10)	 1.09, p	 0.30; dark period REMS: t(10)	 1.72, p	 0.12,
unpaired t test; Fig. 2J–L) and number (light period wakefulness:
t(10) 0.01, p 0.99; dark period wakefulness: t(10)	 0.727, p	
0.48; light period SWS: t(10) 	 0.026, p 	 0.98; dark period
4
(Figure legend continued.) VMP (n	 6). E–G, Time course of hourly wakefulness (E), SWS
(F), and REMS (G) at 1 week after surgery.H–M, Ablation of the VMP resulted in a longermean
duration of wake episodes (H–J), whereas the mean number of each episode was smaller
(K–M). N–P, Ablation of the VMP resulted in higher amounts of wakefulness (N) and lower
amounts of SWS (O) andREMS (P) for at least 4weeks after surgery.White andgraybackground
in each panel indicate light and dark periods, respectively. *p 0.05, **p 0.01 compared
with WT Ctrl/VMP mice. Data are presented as the mean SEM (n	 6). RN, Red nucleus; SN,
substantia nigra; IP, interpeduncular nucleus.
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Figure2. Ablationof theVMPdopaminergicneuronshad little tonoeffectonwakefulness.A, DAT-Cremicewere injectedwithAAV-FLEX-DTA into theVMP.B–E, Brain sections stainedagainst TH(B,D) or
VGATmRNA(C,E) frommice injectedwithAAV-FLEX-DTA(DAT-CreDTA/VMPmice;B,C)orAAV-FLEX-hrGFP(DAT-Cre hrGFP/VMPmice;D,E) toconfirmthat theVMPdopaminergicneuronswereselectivelyablated
inDAT-Cremice. Dashed line delineates the areawith loss of dopaminergic neurons in aDAT-CreDTA/VMPmouse. Scale bar, 500m.F, Number of neurons expressing TH in theVMPofmice injectedwithAAV.
G–I, Timecourseofhourlywakefulness (G), SWS(H), andREMS(I) at1weekafter surgery. J–O, Ablationof theVMPdopaminergicneurons changedneither themeanduration (J–L) nor thenumber (M–O) of
each episode.P–R, Total amount ofwakefulness (P), SWS (Q), andREMS (R) for 12h.White andgraybackground in eachpanel indicate light anddarkperiods, respectively. *p0.05, **p0.01 compared
withDAT-Cre hrGFP/VMPmice. Data are presented as themean SEM (n	 6). RN, Rednucleus; SN, substantia nigra; IP, interpeduncular nucleus.
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SWS: t(10)	 0.654, p	 0.53; light period
REMS: t(10)	 0.232, p	 0.82; dark period
REMS: t(10) 	 1.56, p 	 0.15, unpaired t
test; Fig. 2M–O) of each episode at 1 week
after surgery. Except for a modest de-
crease in wakefulness during the light pe-
riod in the second week after surgery, the
total amount of wakefulness, SWS, or
REMS during the 12 h light or dark
periods was unchanged for up to 4 weeks
after surgery (light period wakefulness:
F(1,10) 	 13.7, p 	 0.0041; dark period
wakefulness: F(1,10) 	 0.0457, p 	 0.84;
light period SWS: F(1,10) 	 6.54, p 	
0.029; dark period SWS: F(1,10) 	 0.0007,
p 	 0.98; light period REMS: F(1,10) 	
0.430, p 	 0.53; dark period REMS:
F(1,10) 	 6.38, p 	 0.030, ANOVA fol-
lowed by Sidak’s post hoc comparisons;
Fig. 2P–R). These findings suggest that
dopaminergic neurons in the VMP are
not required for the sleep–wake patterns
of mice.
VMPGABAergic neuron deficiency
increases wakefulness in mice
We next evaluated the effect of GABAer-
gic neuron ablation in the VMP. DTAwas
focally expressed in the VMP by stereo-
taxic microinjection of AAV-FLEX-DTA
into theVMPofVGAT-Cremice (VGAT-
CreDTA/VMP mice) selectively expressing
the Cre protein in GABAergic neurons
(Vong et al., 2011) (Fig. 3A–C). Control
mice expressed hrGFP in the VMP
GABAergic neurons (VGAT-CrehrGFP/VMP
mice; Fig. 3D,E). The number of cells
positive for VGAT mRNA was decreased
by 97% in theVMPofVGAT-CreDTA/VMP
mice comparedwithVGAT-CrehrGFP/VMP
mice (t(9) 	 19.7, p  0.0001, unpaired t
test; Fig. 3F). Compared with VGAT-
CrehrGFP/VMP mice, VGAT-CreDTA/VMP
mice had largely increased wakefulness
throughout the entire day (F(1,9) 	 31.2,
p	 0.0003, ANOVA; Fig. 3G). Concomi-
tantly, VGAT-CreDTA/VMPmice exhibited
lower amounts of SWS (F(1,9)	 31.8, p	
Figure 3. Ablation of the VMP GABAergic neurons strongly increased wakefulness. A, VGAT-Cre mice were injected with
AAV-FLEX-DTA into the VMP. B–E, Brain sections stained against VGAT mRNA (B, D) or TH (C, E) in mice injected with AAV-FLEX-
DTA (VGAT-Cre DTA/VMPmice;B, C) or AAV-FLEX-hrGFP (VGAT-Cre hrGFP/VMPmice;D, E) to confirm that the VMP GABAergic neurons
were selectively ablated in VGAT-Cre mice. Dashed line delineates the area with loss of GABAergic neurons in a VGAT-Cre DTA/VMP
mouse. Scale bar, 500m. F, Number of neurons expressing VGAT in the VMP of mice injected with AAV. G–I, Time course of
4
wakefulness (G), SWS (H), and REMS (I) amount at 1 week
after surgery. J–O, Ablation of the VMP GABAergic neurons
induced a longer mean duration of wake episodes (J–L),
whereas the mean number of each episode was smaller (M–
O).P–R, Total amount ofwakefulness (P), SWS (Q), and REMS
(R) for 12 h.White and gray background in each panel indicate
light and dark periods, respectively. S, Time course of body
weight changes. *p  0.05, **p  0.01, compared with
VGAT-Cre hrGFP/VMP mice. Data are presented as the mean
SEM [n	 5–6, except for L (n	 4 for light and 2 for dark)
because of the absence of REMS in some VGAT-Cre DTA/VMP
mice, andS (n	8–9)]. RN, Rednucleus; SN, substantia nigra;
IP, interpeduncular nucleus.
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0.0003, ANOVA; Fig. 3H) and REMS
(F(1,9) 	 18.0, p 	 0.0022, ANOVA; Fig.
3I). The mean duration of wake episodes
in VGAT-CreDTA/VMP mice in the light
and dark periods was 20.2 and 24.6 times
longer, respectively, than that in VGAT-
CrehrGFP/VMP mice, although the differ-
ence was not statistically significant (light
period: t(9) 	 2.10, p 	 0.065, unpaired t
test; dark period: t(9) 	 2.10, p 	 0.066,
unpaired t test; Fig. 3J), whereas themean
number of wake episodes in the light
and dark period was 56% (t(9) 	 2.84,
p 	 0.019, unpaired t test) and 70%
(t(9)	 3.59, p	 0.0059, unpaired t test)
lower, respectively (Fig. 3M ). These re-
sults suggest that ablating VMPGABAe-
rgic neurons efficiently consolidates
wakefulness, similar to the effects of
nonselective VMP ablation in animals
(Fig. 1H,K ). For the mean duration,
only SWS during the dark period was
significantly reduced (light period SWS:
t(9) 	 1.41, p 	 0.19; dark period SWS:
t(9) 	 7.25, p  0.0001; unpaired t test;
Fig. 3K ), whereas the episode numbers
of both SWS and REMS were decreased
in VGAT-CreDTA/VMP mice during both
light conditions (light period SWS:
t(9)	 2.80, p	 0.021; dark period SWS:
t(9) 	 3.56, p 	 0.0061; light period
REMS: t(9) 	 2.27, p 	 0.049; dark pe-
riod REMS: t(9) 	 10.9, p  0.0001, un-
paired t test; Fig. 3N,O). The increased
wakefulness in the VGAT-CreDTA/VMP
mice was maintained in both the light
and dark periods for at least 4 weeks
(light period: F(1,9) 	 47.1, p  0.0001;
dark period: F(1,9) 	 98.1, p  0.0001,
ANOVA; Fig. 3P). The SWS and REMS
amounts were concomitantly lower in
VGAT-CreDTA/VMP mice (light period
SWS: F(1,9)	 50.4, p 0.0001; dark period
SWS:F(1,9)	 86.5, p 0.0001; light periodREMS:F(1,9)	 11.9, p	
0.0072; dark period REMS: F(1,9)	 55.3, p 0.0001, ANOVA; Fig.
3Q,R). Despite the long-lasting wake time, the VGAT-CreDTA/VMP
mice appeared healthy although the body weight was slightly, but
significantly, lower than that ofVGAT-CrehrGFP/VMPmice (F(1,15)	
8.42, p	 0.011, ANOVA; Fig. 3S). These findings suggest that the
VMP GABAergic neurons are essential for maintaining sleep–wake
patterns in mice.
Dopamine mediates the increased wakefulness in mice with
VMPGABAergic neuron deficiency
We next investigated the molecular mechanisms of increased
wakefulness in the VGAT-CreDTA/VMP mice using phar-
macologic methods. Because the VMP comprises the VTA and
rostromedial tegmental nucleus GABAergic neurons projecting
to midbrain dopaminergic neurons (Jhou et al., 2009b; Om-
elchenko and Sesack, 2009), we tested whether the dopaminergic
system is involved in the increased wakefulness in VGAT-
CreDTA/VMP mice. Previous studies suggested that dopamine
produces wakefulness via D1 and D2 receptors, so we treated
VGAT-CreDTA/VMP or VGAT-CrehrGFP/VMP mice at 10:00 with
either the selective dopamine D1 receptor antagonist SCH23390
at 0.03 mg kg1, the selective dopamine D2/D3 receptor antago-
nist raclopride at 2 mg kg1, a mixture of SCH23390 and raclo-
pride, or saline as a vehicle control. The mixture of SCH23390
and raclopride decreased wakefulness for 6 h in VGAT-CreDTA/
VMP andVGAT-CrehrGFP/VMPmice after the drug injection, while
neither SCH23390 nor raclopride alone significantly affected
wakefulness in theVGAT-CreDTA/VMP and controlmice, suggest-
ing that dopamine receptors mediate wakefulness under baseline
conditions and in cases of VMP GABAergic neuron deficiency
(Fig. 4A: F(2.06,14.4)	 8.34, p	 0.0037; Fig. 4B: F(2.09,10.4)	 58.3,
p 	 0.0057, ANOVA). In contrast, the histamine H1 receptor
antagonist ketotifen at 10 mg kg1 decreased wakefulness in
VGAT-CrehrGFP/VMP mice (t(4) 	 3.50, p 	 0.025, paired t test;
Fig. 4D), but did not affect wakefulness in VGAT-CreDTA/VMP
mice (t(5)	 0.18, p	 0.86, paired t test; Fig. 4C), suggesting that
histamine H1 receptors do not play an important role in the
increased wakefulness in mice with an absence of GABAergic
neurons in the VMP.
Figure 4. Dopamine receptor antagonists suppressed wakefulness in mice with an absence of GABAergic neurons in the VMP.
Total amount of wakefulness for 6 h in VGAT-Cre DTA/VMP (A, C) or VGAT-Cre hrGFP/VMP mice (B, D) treated with dopamine receptor
antagonists (SCH23390 and/or raclopride;A,B) or the histamineH1 receptor antagonist ketotifen (C,D). Data are presented as the
mean SEM (n	 5–8).
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Chemogenetic inhibition of VMPGABAergic neurons
increases wakefulness
To determine whether inhibition of VMP GABAergic neurons
also affects sleep–wake regulation in mice, we chemogenetically
inhibited these neurons in the VMP of VGAT-Cre mice (VGAT-
CreM4/VMP mice; Fig. 5A,B) using inhibitory designer receptors
exclusively activated by designer drugs (DREADD) hM4Di,
which suppress neuronal activity when the ligandCNO is applied
Figure 5. Chemogenetic inhibition of the VMPGABAergic neurons increasedwakefulness.A, VGAT-Cremicewere injectedwith AAV-FLEX-hM4Di-mCherry into the VMP (VGAT-CreM4/VMPmice).
B, Brain sections were stained against mCherry to confirm that the hM4Di-mCherry protein was expressed in the VMP. Scale bar, 500m. C, Representative trace of current-clamp recording from
a hM4Di-expressing neuron. The solid bar indicates the duration of 5M CNO application. The dotted line denotes 0 mV. D, Mean firing rate of hM4Di-expressing neurons before and after CNO
application (n	 8 cells from 3 mice). Data obtained from the same cell are connected with a line. E, Time course of hourly wakefulness. F–H, Chemogenetic inhibition increased the mean wake
episodeduration (F) and total amount ofwakefulness (H),whereas thenumber ofwake episodes (G)was reduced for 4 h after 3mgkg1 CNO injection. I, CNOapplicationdid not affect sleep–wake
amounts in naive VGAT-Cre mice. *p 0.05, **p 0.01 compared with saline. Data are presented as the mean SEM (n	 7–8). RN, Red nucleus; SN, substantia nigra; IP, interpeduncular
nucleus.
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(Urban and Roth, 2015). Whole-cell
patch-clamp recordings in acute slices
were performed to test the response of a
single hM4Di-expressing VMP neuron to
CNO application in a VGAT-CreM4/VMP
mouse.We bath-applied 5MCNO to the
brain slices and found that CNO reduced
the firing rate of VMP neurons expressing
hM4Di from 7.4  2.1 to 0.04  0.03
spikes/s (t(7) 	 3.55, p 	 0.0094, paired t
test; Fig. 5C,D). Intraperitoneal adminis-
tration of 3 mg kg1 CNO to VGAT-
CreM4/VMP mice at 10:00, when mice
spend most of their time asleep, increased
wakefulness for 4 h after the injection (Fig.
5E: F(1,7)	 5.99, p	 0.044, ANOVA; Fig.
5H: t(7)	 7.19, p	 0.0002, paired t test).
CNO increased the mean wake episode
duration by 4.6-fold (t(7) 	 5.49, p 	
0.0009, paired t test) and decreased the
mean episode number by 58% (t(7) 	
4.26, p	 0.0038, paired t test) (Fig. 5F,G),
similar to that inVGAT-CreDTA/VMPmice
(Fig. 3 J,M). CNOadministration at 10:00
did not affect the sleep–wake behavior of
naive VGAT-Cre mice (wakefulness:
F(1,6)	 0.14, p	 0.72; SWS: F(1,6)	 1.16,
p 	 0.32; REMS: F(1,6) 	 0.65, p 	 0.45,
ANOVA; Fig. 5I). These results suggest
that wakefulness is also increased by tran-
sient inhibition of VMP GABAergic
neurons.
Blocking dopamine receptors abolishes
the increased wakefulness by inhibition
of VMPGABAergic neurons
Next, we investigated whether dopamine
receptors contribute to the increased
wakefulness after chemogenetic inhibi-
tion of VMP GABAergic neurons using
SCH23390andraclopride.VGAT-CreM4/VMP
mice were pretreated with saline, 0.03 mg
kg1 SCH23390, 2mg kg1 raclopride, or
a mixture of SCH23390 and raclopride 30
min before the CNO injection at 10:00. In
VGAT-CreM4/VMP mice pretreated with
SCH23390 or raclopride, CNO still in-
creased wakefulness for several hours,
although the total amount of wakeful-
ness for 4 h after CNO injection was sig-
nificantly decreased by both antagonists
(Fig. 6A: F(1,6) 	 29.4, p 	 0.0016; Fig.
6B: F(1,6) 	 38.6, p 	 0.0008; Fig. 6C:
F(1,6) 	 25.2, p 	 0.0024; Fig. 6E:
F(3,18) 	 72.9, p  0.0001, ANOVA).
Conversely, CNO injection did not in-
duce wakefulness when mice were pre-
treated with the mixture of SCH23390
and raclopride (Fig. 6D: F(1,6) 	 22.9,
p	 0.003, ANOVA; Fig. 6E), indicating
that dopamine receptors mediate for the
wake effect after inhibition of VMP
GABAergic neurons.
Figure 6. Dopamine receptor antagonists blocked the wake effect caused by inhibition of the VMP GABAergic system. A–D,
Time course of wakefulness in VGAT-CreM4/VMP mice administered CNO after pretreatment with saline (A), SCH23390 (B), raclo-
pride (C), or SCH23390 and raclopride (D). E, Total amount of wakefulness for 4 h after injecting CNO in VGAT-CreM4/VMP mice
pretreated with dopamine receptor antagonists. *p 0.05, **p 0.01 compared with saline. n.s., Not significant. Data are
presented as the mean SEM (n	 7).
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Chemogenetic activation of VMP
GABAergic neurons induces SWS
To further examine the role of VMP
GABAergic neurons in sleep–wake regu-
lation, we introduced an excitatory DRE-
ADD hM3Dq that evokes neuronal
excitation by administering CNO to
VGAT-Cre mice (VGAT-CreM3/VMP
mice; Fig. 7A). Whole-cell patch-clamp
recordings in acute slices containing the
VMP revealed that the application of 5M
CNO increased the firing rate of hM3Dq-
expressing VMP neurons in VGAT-
CreM3/VMP mice from 5.6 1.3 to 13.4
3.0 spikes/s (t(6)	 2.82, p	 0.030, paired
t test; Fig. 7B,C). Intraperitoneal admin-
istration of CNO to VGAT-CreM3/VMP
mice at 20:00 drastically decreased wake-
fulness (F(3,9) 	 259.9, p  0.0001,
ANOVA) and increased SWS (F(3,9) 	
337.9, p  0.0001, ANOVA) for 7 h after
the injection (Fig. 7D,E). Interestingly,
CNO also decreased the amount of REMS
(F(3,9) 	 22.4, p 	 0.0002, ANOVA) for
up to 10 h after the injection (Fig. 7F).
CNO dose-dependently decreased the
meanwake episode duration (F(1.02,3.05)	
41.9, p 	 0.0071, ANOVA; Fig. 7G) for
12 h after the injection, but did not change
the sleep episode duration (Fig. 7H:
F(1.39,4.16) 	 1.93, p 	 0.246; Fig. 7I:
F(1.60,4.81) 	 1.80, p 	 0.255, ANOVA).
Conversely, CNO increased the number
of both wake (F(1.67,5.02) 	 73.2, p 	
0.0002, ANOVA; Fig. 7J) and SWS
(F(1.69,5.07) 	 76.2, p 	 0.0002, ANOVA;
Fig. 7K) episodes, whereas the number of
REMS episodes was reduced (F(1.74,5.21)	
9.98, p 	 0.018, ANOVA; Fig. 7L). The
total amount of each state during the 12 h
after injection indicated that CNO dose-
dependently decreased wakefulness
(F(1.91,5.72)	 259.6, p 0.0001, ANOVA;
Fig. 7M) and REMS (F(2.00,5.99) 	 22.5,
p 	 0.016, ANOVA; Fig. 7O), and in-
creased SWS (F(1.98,5.95) 	 337.4, p 
0.0001, ANOVA; Fig. 7N). CNO did not
change the EEG power spectrum during
SWS (F(3,9) 	 1.317, p 	 0.33, ANOVA;
Fig. 7P). CNO administration at 20:00 did
not affect sleep–wake behavior in naive
VGAT-Cre mice (wakefulness: F(1,5) 	
3.28, p 	 0.13; SWS: F(1,5) 	 3.33, p 	
0.13; REMS: F(1,5) 	 3.34, p 	 0.13,
Figure 7. Chemogenetic activation of the VMP GABAergic neurons reduced wakefulness and induced SWS. A, VGAT-Cre mice
were injected with AAV-FLEX-hM3Dq-mCherry into the VMP (VGAT-CreM3/VMP mice). B, Representative trace of current-clamp
recording from a hM3Dq-expressing neuron. The solid bar indicates the duration of 5M CNO application. The dotted line denotes
0mV. C, Mean firing rate of hM3Dq-expressing neurons before and after CNO application (n	 7 cells from 3mice). Data obtained
from the same cell are connected with a line. D–F, Time course of hourly wakefulness (D), SWS (E), and REMS (F). G–O, Mean
4
episode duration (G–I), number of episodes (J–L), and total
amount (M–O) of wakefulness (G, J, M), SWS (H, K, N), and
REMS (I, L,O) for 12hafter CNO injection.P, EEGpowerdensity
during SWS. Q, CNO (3 mg kg1) application did not affect
sleep–wake amounts in naive VGAT-Cre mice. *p  0.05,
**p 0.01 compared with saline. Data are presented as the
mean SEM (n	 4).
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ANOVA; Fig. 7Q). These results suggest that chemogenetic acti-
vation of VMP GABAergic neurons decreased wakefulness by
disrupting the maintenance of wake episodes, likely by inducing
SWS.
VMPGABAergic neurons are active during the active period
Finally, we examined the patterns of spontaneous activity of the
VMP GABAergic neurons by immunohistochemical investiga-
tion of the expression of c-Fos, a marker of neuronal activation,
inVGAT-CreM4/VMPmice (Fig. 8A,B).Mice that were killed dur-
ing the dark period at 24:00 spent more time (128  3.3 min)
awake during the 3 h before being killed than mice that were
killed during the light period at 12:00 when they woke 45  4.0
min during the 3 h before they were killed (t(14) 	 15.9, p 
0.0001, unpaired t test; Fig. 8C). Double labeling for c-Fos and
mCherry revealed that mice killed during the dark period had a
markedly higher number of hM4Di-mCherry-positive VMP
neurons expressing c-Fos (44 3.7%) thanmice that were killed
during the light period with c-Fos expression observed in 22 
4.3% of hM4Di-mCherry-positive VMP neurons (t(14) 	 3.99,
p	 0.0013, unpaired t test; Fig. 8D). These results suggest that the
activity of VMP GABAergic neurons is higher during the active
period than during the inactive period.
Discussion
Ablation of cells in the VMP led to a severe and long-lasting (at
least 4 weeks) wake effect in mice, consistent with previous re-
ports that nonspecific cytotoxic lesions of ventral areas in the
midbrain and pons of cats (Lai et al., 1999) increases wakefulness.
Further analysis of the neuronal and molecular mechanisms of
the VMP involved in regulating wakefulness revealed that defi-
ciency or inhibition of VMP GABAergic neurons promotes
wakefulness through dopamine receptors. Activation of VMP
GABAergic neurons strongly induced SWS and reducedwakeful-
ness. These findings suggest that the VMP GABAergic neurons
are key components for the control of sleep and wakefulness in
mice.
Previous studies indicated that dopamine and its D1 and D2
receptors play a role in promoting wakefulness (Oishi and
Lazarus, 2017). Pharmacologic experiments demonstrated that
administration of D1 or D2 receptor agonists increases wakeful-
ness (Monti et al., 1988, 1989; Trampus et al., 1991, 1993; Isaac
and Berridge, 2003), whereas D1 or D2 receptor antagonists sup-
press wakefulness (Trampus and Ongini, 1990; Trampus et al.,
1991; Ongini et al., 1993; Eder et al., 2003). D2 receptor knock-
out mice sleep more than WT mice and the arousal effect of
modafinil, a widely used wake-promoting drug for treating the
sleep disorder narcolepsy, is strongly attenuated in the knock-out
mice (Qu et al., 2008). DAT knock-out mice exhibit a higher
amount of wakefulness compared with WT mice and are unre-
sponsive tomodafinil (Wisor et al., 2001). These data implicating
a role of dopamine systems in promoting wakefulness, together
with our observation that dopamine receptors mediate increased
wakefulness after ablation or inhibition of VMPGABAergic neu-
rons, suggest that these inhibitory neurons control wakefulness
by suppressing dopaminergic systems.
The circuit between VMP GABAergic and dopamine rece-
ptor-expressing neurons for the control of wakefulness remains
unclear. The VMP contains the VTA and rostromedial tegmental
nucleus, both of which send projections to brain areas containing
dopaminergic neurons, including the VTA, substantia nigra, and
dorsal raphe, also known as the ventral periaqueductal gray mat-
ter (Jhou et al., 2009a,b; Omelchenko and Sesack, 2009; Taylor et
al., 2014). Chemogenetic (Oishi et al., 2017a) or optogenetic
(Eban-Rothschild et al., 2016; Taylor et al., 2016) activation of
VTA dopaminergic neurons strongly promotes wakefulness.
Moreover, lesion (Lu et al., 2006) and optogenetic activation
(Cho et al., 2017) studies revealed that dorsal raphe dopaminer-
gic neurons also play a role in regulating wakefulness. Therefore,
the VMPGABAergic neurons may control wakefulness by inhib-
iting one or more area with wake-active dopaminergic neurons.
Our data suggest that VMP GABAergic neurons are more
activated during the dark period, in which mice spend more
time in wakefulness compared with the light period. Meth-
odologic limitations must be kept in mind, however, when
using c-Fos analysis. The activity of VMP GABAergic neurons
may be affected by circadian factors that vary between light
and dark periods. In addition, c-Fos expression in neurons
likely reflects their activity over several hours and thus c-Fos
analysis may lack the temporal resolution to examine frequent
behavioral state changes, that is, sleep–wake transitions, in
mice. Conversely, c-Fos expression is a classic, well validated
marker of neuronal activation used to identify important
sleep–wake-related neurons (Sherin et al., 1996; Anaclet et al.,
2012; Oishi et al., 2017b). Considering that activation or inhi-
bition of the activity of these neurons decreases or increases
wakefulness, respectively, we suspect that the function of VMP
GABAergic neurons in sleep–wake regulation may be to in-
hibit wake-promoting systems during wakefulness to prevent
an excessive amount of wakefulness.
The VTA GABAergic neurons increase c-Fos expression after
REMS rebound (Maloney et al., 2002; Sapin et al., 2009), suggest-
ing that the neurons are more active during REMS. Surprisingly,
however, our results indicate that chemogenetic activation of
VMPGABAergic neurons decreases REMS (Fig. 7). Although the
function of VTA GABAergic neurons during REMS remains un-
clear, these neurons may be active during REMS to avoid unnec-
essary REMS. Alternatively, it is possible that there are one or
more GABAergic populations in the VMP (other thanVTA)with
Figure 8. VMP GABAergic neurons exhibited higher c-Fos expression during night. A, Example of double-labeled cells (indicated by arrows) for c-Fos (green) andmCherry (GABAergic cells; red)
counterstainedwith DAPI (nuclei; blue) in VGAT-CreM4/VMPmice. Scale bar, 10m.B, Line drawings showing typical distribution of c-Fos/mCherry double-labeled cells (red circles). C,Wakefulness
during 3 h before killing the mice. D, Percentage of double-positive neurons for c-Fos andmCherry amongmCherry-positive neurons in the VMP. **p 0.01 compared with light period. Data are
presented as the mean SEM (n	 8). RN, Red nucleus; SN, substantia nigra; IP, interpeduncular nucleus.
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strong REMS-suppressing ability. More detailed neuroanatomic
studies are required to clarify the roles of VMP GABAergic neu-
rons in REMS regulation.
VTA dopaminergic neurons have a strong ability to promote
wakefulness (Eban-Rothschild et al., 2016; Oishi et al., 2017a),
but ablation of VTA dopaminergic neurons in the VMP in mice
did not result in obvious changes in wakefulness (Fig. 3). Al-
though this is not consistent with the decreased wakefulness
induced by chemogenetic inhibition of VTA dopaminergic neu-
rons reported by another group using a different Cre mouse line
(Eban-Rothschild et al., 2016), it is consistent with findings from
our previous study that chemogenetic inhibition of VTA dopa-
minergic neurons did not alter the amount of wakefulness in
DAT-Cre mice (Oishi et al., 2017a). A potential reduction in
wakefulness caused by a deficiency of VTA dopaminergic neu-
rons may be compensated for by other wake-promoting systems.
It is also plausible, however, that VTA dopaminergic neurons are
tonically silenced by VMP GABAergic neurons and require sa-
lient stimuli to become wake-active (Bromberg-Martin et al.,
2010; Eban-Rothschild et al., 2016).
In conclusion, our study revealed a GABAergic ventral mid-
brain/pons area that regulates sleep–wakefulness through dopa-
minergic systems. Further studies to examine the neuroanatomic
or neurochemical dissociation of the VMP are required to clarify
how the level of wakefulness is regulated by VMP GABAergic
neurons.
References
Anaclet C, Lin JS, Vetrivelan R, Krenzer M, Vong L, Fuller PM, Lu J (2012)
Identification and characterization of a sleep-active cell group in the ros-
tral medullary brainstem. J Neurosci 32:17970–17976. CrossRef Medline
Ba¨ckmanCM,MalikN, Zhang Y, Shan L, Grinberg A,Hoffer BJ,Westphal H,
Tomac AC (2006) Characterization of a mouse strain expressing cre re-
combinase from the 3 untranslated region of the dopamine transporter
locus. Genesis 44:383–390. CrossRef Medline
Bromberg-Martin ES,MatsumotoM,HikosakaO (2010) Dopamine inmo-
tivational control: rewarding, aversive, and alerting. Neuron 68:815–834.
CrossRef Medline
Cho JR, Treweek JB, Robinson JE, Xiao C, Bremner LR, Greenbaum A, Gra-
dinaru V (2017) Dorsal raphe dopamine neurons modulate arousal
and promote wakefulness by salient stimuli. Neuron 94:1205–1219.e8.
CrossRef Medline
Eban-Rothschild A, Rothschild G, GiardinoWJ, Jones JR, de Lecea L (2016)
VTA dopaminergic neurons regulate ethologically relevant sleep–wake
behaviors. Nat Neurosci 19:1356–1366. CrossRef Medline
Eder DN, Zdravkovic M, Wildschiødtz G (2003) Selective alterations of the
first NREM sleep cycle in humans by a dopamine D1 receptor antagonist
(NNC-687). J Psychiatr Res 37:305–312. CrossRef Medline
GerashchenkoD, Blanco-CenturionCA,Miller JD, Shiromani PJ (2006) In-
somnia following hypocretin2-saporin lesions of the substantia nigra.
Neuroscience 137:29–36. CrossRef Medline
Guillery RW (2002) On counting and counting errors. J Comp Neurol 447:
1–7. CrossRef Medline
Isaac SO, Berridge CW (2003) Wake-promoting actions of dopamine D1
and D2 receptor stimulation. J Pharmacol Exp Ther 307:386–394.
CrossRef Medline
JhouTC,Geisler S,MarinelliM,DegarmoBA, ZahmDS (2009a) Themeso-
pontine rostromedial tegmental nucleus: a structure targeted by the lat-
eral habenula that projects to the ventral tegmental area of Tsai and
substantia nigra compacta. J Comp Neurol 513:566–596. CrossRef
Medline
Jhou TC, Fields HL, BaxterMG, Saper CB, Holland PC (2009b) The rostro-
medial tegmental nucleus (RMTg), a GABAergic afferent to midbrain
dopamine neurons, encodes aversive stimuli and inhibits motor re-
sponses. Neuron 61:786–800. CrossRef Medline
Jones BE, Bobillier P, Pin C, Jouvet M (1973) The effect of lesions of
catecholamine-containing neurons upon monoamine content of the
brain and EEG and behavioral waking in the cat. Brain Res 58:157–177.
CrossRef Medline
Kaur S, Wang JL, Ferrari L, Thankachan S, Kroeger D, Venner A, Lazarus M,
Wellman A, Arrigoni E, Fuller PM, Saper CB (2017) A genetically de-
fined circuit for arousal from sleep during hypercapnia. Neuron 96:1153–
1167.e5. CrossRef Medline
KrashesMJ, Koda S, YeC, Rogan SC, AdamsAC, CusherDS,Maratos-Flier E,
RothBL, Lowell BB (2011) Rapid, reversible activation of AgRPneurons
drives feeding behavior in mice. J Clin Invest 121:1424–1428. CrossRef
Medline
Lai YY, Shalita T, Hajnik T, Wu JP, Kuo JS, Chia LG, Siegel JM (1999)
Neurotoxic N-methyl-D-aspartate lesion of the ventral midbrain and
mesopontine junction alters sleep–wake organization. Neuroscience 90:
469–483. CrossRef Medline
Lazarus M, Shen HY, Cherasse Y, Qu WM, Huang ZL, Bass CE, Winsky-
Sommerer R, Semba K, Fredholm BB, Boison D, Hayaishi O, Urade Y,
Chen JF (2011) Arousal effect of caffeine depends on adenosine A2A
receptors in the shell of the nucleus accumbens. J Neurosci 31:10067–
10075. CrossRef Medline
Lu J, Jhou TC, Saper CB (2006) Identification of wake-active dopaminergic
neurons in the ventral periaqueductal graymatter. JNeurosci 26:193–202.
CrossRef Medline
Maloney KJ, Mainville L, Jones BE (2002) c-fos expression in dopaminergic
and GABAergic neurons of the ventral mesencephalic tegmentum after
paradoxical sleep deprivation and recovery. Eur J Neurosci 15:774–778.
CrossRef Medline
Monti JM,HawkinsM, JantosH,D’Angelo L, FernandezM (1988) Biphasic
effects of dopamineD-2 receptor agonists on sleep andwakefulness in the
rat. Psychopharmacology (Berl) 95:395–400. Medline
Monti JM, Jantos H, Ferna´ndez M (1989) Effects of the selective dopamine
D-2 receptor agonist, quinpirole on sleep and wakefulness in the rat. Eur
J Pharmacol 169:61–66. CrossRef Medline
Oishi Y, Lazarus M (2017) The control of sleep and wakefulness by me-
solimbic dopamine systems. Neurosci Res 118:66–73. CrossRef Medline
Oishi Y, Takata Y, Taguchi Y, Kohtoh S, Urade Y, Lazarus M (2016) Poly-
graphic recording procedure for measuring sleep in mice. J Vis Exp 107:
e53678. CrossRef Medline
Oishi Y, Suzuki Y, Takahashi K, Yonezawa T, Kanda T, Takata Y, Cherasse Y,
Lazarus M (2017a) Activation of ventral tegmental area dopamine neu-
rons produces wakefulness through dopamine D2-like receptors in mice.
Brain Struct Funct 222:2907–2915. CrossRef Medline
Oishi Y, XuQ,Wang L, Zhang BJ, Takahashi K, Takata Y, Luo YJ, Cherasse Y,
Schiffmann SN, de Kerchove d’Exaerde A, Urade Y, QuWM, Huang ZL,
Lazarus M (2017b) Slow-wave sleep is controlled by a subset of nucleus
accumbens core neurons inmice. Nat Commun 8:734. CrossRefMedline
OmelchenkoN, Sesack SR (2009) Ultrastructural analysis of local collaterals
of rat ventral tegmental area neurons: GABA phenotype and synapses
onto dopamine and GABA cells. Synapse 63:895–906. CrossRef Medline
Ongini E, Bonizzoni E, Ferri N, Milani S, Trampus M (1993) Differential
effects of dopamine D-1 and D-2 receptor antagonist antipsychotics on
sleep–wake patterns in the rat. J Pharmacol Exp Ther 266:726–731.
Medline
Paxinos G, Franklin K (2001) The mouse brain in stereotaxic coordinates.
San Diego, CA: Academic.
QuWM, Huang ZL, Xu XH, Matsumoto N, Urade Y (2008) Dopaminergic
D1 and D2 receptors are essential for the arousal effect of modafinil.
J Neurosci 28:8462–8469. CrossRef Medline
Sapin E, Lapray D, Be´rod A, Goutagny R, Le´ger L, Ravassard P, Cle´ment O,
Hanriot L, Fort P, Luppi PH (2009) Localization of the brainstem
GABAergic neurons controlling paradoxical (REM) sleep. PLoS One
4:e4272. CrossRef Medline
Sherin JE, Shiromani PJ, McCarley RW, Saper CB (1996) Activation of ven-
trolateral preoptic neurons during sleep. Science 271:216–219. CrossRef
Medline
Siegel JM (2009) Sleep viewed as a state of adaptive inactivity. Nat Rev Neu-
rosci 10:747–753. CrossRef Medline
Taylor NE, Van Dort CJ, Kenny JD, Pei J, Guidera JA, Vlasov KY, Lee JT,
Boyden ES, Brown EN, Solt K (2016) Optogenetic activation of dopa-
mine neurons in the ventral tegmental area induces reanimation from
general anesthesia. Proc Natl Acad Sci U S A 113:12826–12831. CrossRef
Medline
Taylor SR, Badurek S, Dileone RJ, Nashmi R, Minichiello L, Picciotto MR
Takata et al. • Sleep–Wake Control by Mesopontine GABA J. Neurosci., November 21, 2018 • 38(47):10080–10092 • 10091
(2014) GABAergic and glutamatergic efferents of the mouse ventral teg-
mental area. J Comp Neurol 522:3308–3334. CrossRef Medline
Trampus M, Ongini E (1990) The D1 dopamine receptor antagonist SCH
23390 enhances REM sleep in the rat. Neuropharmacology 29:889–893.
CrossRef Medline
Trampus M, Ferri N, Monopoli A, Ongini E (1991) The dopamine D1 re-
ceptor is involved in the regulation of REM sleep in the rat. Eur J Phar-
macol 194:189–194. CrossRef Medline
TrampusM, Ferri N, AdamiM,Ongini E (1993) The dopamineD1 receptor
agonists, A68930 and SKF 38393, induce arousal and suppress REM sleep
in the rat. Eur J Pharmacol 235:83–87. CrossRef Medline
Unno K, Ozaki T, Mohammad S, Tsuno S, Ikeda-Sagara M, Honda K, Ikeda
M (2012) First and second generation H(1) histamine receptor antago-
nists produce different sleep-inducing profiles in rats. Eur J Pharmacol
683:179–185. CrossRef Medline
Urban DJ, Roth BL (2015) DREADDs (designer receptors exclusively acti-
vated by designer drugs): chemogenetic tools with therapeutic utility.
Annu Rev Pharmacol Toxicol 55:399–417. CrossRef Medline
Vong L, Ye C, Yang Z, Choi B, Chua S Jr, Lowell BB (2011) Leptin action on
GABAergic neurons prevents obesity and reduces inhibitory tone to
POMC neurons. Neuron 71:142–154. CrossRef Medline
Wisor JP, Nishino S, Sora I, Uhl GH,Mignot E, Edgar DM (2001) Dopami-
nergic role in stimulant-induced wakefulness. J Neurosci 21:1787–1794.
CrossRef Medline
10092 • J. Neurosci., November 21, 2018 • 38(47):10080–10092 Takata et al. • Sleep–Wake Control by Mesopontine GABA
